Recombinant Protein Market Size, Share & Industry Analysis, By Product Type (Hormone, Growth Factors Enzymes Antibodies, Others), By Application (Research, Therapeutics, Biotechnology, Disease Diagnostics, Others), By End-user(Pharmaceutical & Biotechnology Industries, Academic & Research Institutes, Diagnostic Centres, Others) and Regional Forecast, 2024-2032

The proteins which are expressed artificially by using the tools involved in recombinant DNA (rDNA) technology can be called as recombinant proteins. To express a recombinant protein, a DNA molecule of which the protein is desired is identified, isolated, cloned in an appropriate vector, and finally expressed in a suitable host expression system. Inside the host expression system, this rDNA molecule expressed to produce recombinant protein. The recombinant DNA technology provides a more efficient method to obtain large amounts of proteins. These proteins have a wide variety of applications in detergents, cosmetics, feed additives, food productions, diagnostics, vaccines, and therapeutics. Furthermore, recombinant proteins are highly operative, and shows an essential role in the treatment of certain diseases, for instance, hemophilia. The majority of such recombinant proteins; are derived from human proteins to compensate for the defects of functional proteins in vivo, or to upsurge protein function in a body.

Factors such as escalation in incident and prevalence of cancer and increasing research and development (R&D) activity has increased the focus towards biosimilar, biologics as well as the recombinant proteins productions.

Key Market Driver -

Increased expenditure in R&D and increased focus towards biologic products

Key Market Restraint -

technical expertise and high cost.

According to the International Agency for Research on Cancer 2018, cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018. Apart from this, the growing use of recombinant proteins in clinical diagnostics techniques such as ELISA, Western Blotting, and Immunohistochemistry (IHC) is likely to propel the market growth. The overall recombinant protein market is expected to witness significant growth during the forecast period due to factors such as increased R&D investment, rise in the number of cancer patients, demand for innovative and personalized medicines and other industrial needs such as detergent and diagnostics.

However, the production of recombinant proteins demands important rearrangements of the coding sequence as well as technical expertise which may put high cost and technical barriers in due course that may obstruct the market.

Market Segmentation:

Globally, the recombinant protein market can be segmented on the bases of the type of product, applications, end-users, and region. Based on the type of the product the market can be segmented into hormone, growth factors, enzymes, antibodies, and others. Based on the applications, the market can be segmented into research, therapeutics, biotechnology, disease diagnostics and others. Based on the end-users, the market can be segmented into biotechnology industries, pharmaceutical companies, Research Organizations & Laboratories, Diagnostic Centers, and Others. Geographically, the perfusion systems market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. 

Key Players Covered:

Some of the major companies that are present in the recombinant proteins systems market are Prospec-Tany Technogene Ltd., Abcam plc., Thermo Fisher Scientific, Sigma Aldrich Company, GE Healthcare, GenScript Biotech Corporation, BPS Bioscience, and others

Key Insights:

• Prevalence of Chronic Diseases by Major Countries/Region, 2019


• Introduction of New Products/Approvals (By Major Players)


• New Product Launches


• Key Industry Developments Mergers, Acquisitions, And Collaborations, 2019

Regional Analysis:

Geographically, the recombinant protein market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North American region is likely to hold the largest share of the market and is anticipated to follow the same momentum over the forecast period owing to the increasing expenditure in research. The United States is anticipated to witness the highest growth, due to the plethora of world-class research universities and academic medical centers. Moreover, the R&D spending of the United States is quite higher than in most of the regions. For instance, in 2014, the United States witnessed highest R&D investments in biotechnology and, since then, the US biotechnology research and investment has been growing at a steady rate. Europe is projected to be the second most productive market throughout the forecast period.

To gain extensive insights into the market, Request for Customization

The development of new products and partnership activities of biotechnology companies is likely to boost the growth of the recombinant protein market in this region. However, Asia-Pacific possesses the high market potential for the growth of the market due to an increase in the purchasing power of the countries of this region and R&D expenditure. Various government initiatives across different countries will impact the market outlook over the projected timeframe. For example, India introduced the “Make in India” campaign a few years ago to convey in a large number of investments into the manufacturing and research sectors. Investments are also being made in the pharmaceutical and biotechnology industry segments, which will help boost the production and use of recombinant proteins. This fast-growing startup space in the country stimulated by the influx of capital will encourage added research and development efforts toward building advanced technologies.

Segmentation

Recombinant Protein Market Industry Developments

• In November 2019, Abcam plc. announced a strategic partnership with BrickBio, Inc. to introduce conjoin-prepared sites into immunoglobulins and other proteins in bacterial as well as in mammalian expression systems.


• In December 2019, Guangzhou Development District Investment Promotion Bureau (GDD) and GE Healthcare Life Sciences made a contract to invest 10 million USD together to set up the Guangzhou Bioprocess Academy.